$60,000 of GENMAB lobbying was just disclosed, from Q4 of 2025, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"General Medicare/Medicaid Issues. 340B Issues. Prescription Drug Pricing. Implementation of Inflation Reduction Act of 2022."
You can find more data on corporate lobbying on Quiver Quantitative.
GMAB Hedge Fund Activity
We have seen 171 institutional investors add shares of GMAB stock to their portfolio, and 93 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PARADIGM BIOCAPITAL ADVISORS LP added 3,816,851 shares (+inf%) to their portfolio in Q3 2025, for an estimated $117,062,820
- CITADEL ADVISORS LLC removed 3,517,711 shares (-98.6%) from their portfolio in Q3 2025, for an estimated $107,888,196
- ORBIS ALLAN GRAY LTD added 3,157,606 shares (+39.9%) to their portfolio in Q3 2025, for an estimated $96,843,776
- MARSHALL WACE, LLP removed 1,374,075 shares (-72.0%) from their portfolio in Q3 2025, for an estimated $42,142,880
- MORGAN STANLEY removed 1,022,561 shares (-37.9%) from their portfolio in Q3 2025, for an estimated $31,361,945
- PERPETUAL LTD added 827,217 shares (+inf%) to their portfolio in Q4 2025, for an estimated $25,478,283
- VOLORIDGE INVESTMENT MANAGEMENT, LLC removed 818,363 shares (-86.2%) from their portfolio in Q3 2025, for an estimated $25,099,193
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
GMAB Analyst Ratings
Wall Street analysts have issued reports on $GMAB in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 01/20/2026
- Truist Securities issued a "Buy" rating on 11/07/2025
- Guggenheim issued a "Buy" rating on 09/24/2025
To track analyst ratings and price targets for GMAB, check out Quiver Quantitative's $GMAB forecast page.
GMAB Price Targets
Multiple analysts have issued price targets for $GMAB recently. We have seen 4 analysts offer price targets for $GMAB in the last 6 months, with a median target of $43.0.
Here are some recent targets:
- Raghuram Selvaraju from HC Wainwright & Co. set a target price of $39.0 on 01/20/2026
- Asthika Goonewardene from Truist Securities set a target price of $48.0 on 11/07/2025
- Michael Schmitz from Guggenheim set a target price of $43.0 on 09/24/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
